Weixing Li Selected Research

N- bis- (3- phenyl- propyl)9- oxo- fluorene- 2,7- diamide

12/2005	Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide.
7/2003	Post-treatment with a novel PARG inhibitor reduces infarct in cerebral ischemia in the rat.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Weixing Li Research Topics

Disease

3	Neoplasm Metastasis (Metastasis) 12/2019 - 12/2005
2	Leukemia 01/2021 - 12/2020
2	Breast Neoplasms (Breast Cancer) 01/2021 - 08/2013
2	Intervertebral Disc Displacement (Herniated Disc) 01/2020 - 10/2019
2	Diabetes Mellitus 03/2015 - 09/2006
2	Neuralgia (Stump Neuralgia) 03/2006 - 05/2003
1	Dehydration (Water Stress) 01/2022
1	Surgical Wound 01/2021
1	Colonic Neoplasms (Colon Cancer) 12/2019
1	Hepatocellular Carcinoma (Hepatoma) 12/2019
1	Carcinoma (Carcinomatosis) 12/2019
1	Necrosis 12/2019
1	Rupture 12/2016
1	Neoplasms (Cancer) 01/2015
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2015
1	Alopecia (Baldness) 01/2015
1	Burns 01/2015
1	Macular Degeneration (Age-Related Maculopathy) 01/2015
1	Hypertension (High Blood Pressure) 06/2014
1	Essential Hypertension 06/2014
1	Postmenopausal Osteoporosis 01/2013
1	Mouth Neoplasms (Oral Cancer) 01/2013
1	Nonsyndromic Deafness 10/2007
1	Bilateral Hearing Loss 10/2007
1	Hearing Loss (Hearing Impairment) 10/2007
1	Deafness (Deaf Mutism) 10/2007
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 03/2006
1	Stroke (Strokes) 03/2006
1	Prostatic Neoplasms (Prostate Cancer) 03/2006
1	Melanoma (Melanoma, Malignant) 12/2005
1	Experimental Melanoma 12/2005
1	Shock 04/2005
1	Brain Infarction 07/2003
1	Ischemia 07/2003
1	Brain Ischemia (Cerebral Ischemia) 07/2003

Drug/Important Bio-Agent (IBA)

3	Pharmaceutical PreparationsIBA 12/2020 - 03/2006
2	Member 2 Subfamily G ATP Binding Cassette TransporterIBA 01/2021 - 12/2020
2	Biomarkers (Surrogate Marker)IBA 12/2020 - 01/2013
2	N- bis- (3- phenyl- propyl)9- oxo- fluorene- 2,7- diamideIBA 12/2005 - 07/2003
1	Ethanol (Ethyl Alcohol)IBA 01/2022
1	tucatinibIBA 01/2021
1	Cytotoxins (Cytolysins)IBA 01/2021
1	Tyrosine Kinase InhibitorsIBA 01/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2021
1	KD025IBA 12/2020
1	Antineoplastic Agents (Antineoplastics)IBA 12/2020
1	Adenosine Triphosphate (ATP)IBA 12/2020
1	Ropivacaine (Naropin)FDA LinkGeneric 12/2019
1	Oxygen (Dioxygen)IBA 12/2016
1	HydrogenIBA 12/2016
1	Transfer RNA (tRNA)IBA 03/2015
1	OT-551IBA 01/2015
1	nitroxylIBA 01/2015
1	Ophthalmic Solutions (Eye Drops)IBA 01/2015
1	ProdrugsIBA 01/2015
1	Hydroxylamine (Hydroxylamine Hydrochloride)IBA 01/2015
1	tempolIBA 01/2015
1	Cytochrome P-450 CYP11B2 (CYP11B2)IBA 06/2014
1	Guanine NucleotidesIBA 08/2013
1	Epidermal Growth Factor (EGF)IBA 08/2013
1	Blood Proteins (Serum Proteins)IBA 01/2013
1	Glutathione Transferase (Glutathione S-Transferase)IBA 01/2013
1	AminoglycosidesIBA 10/2007
1	Mitochondrial DNA (mtDNA)IBA 10/2007
1	12S ribosomal RNAIBA 10/2007
1	Leu Transfer RNAIBA 09/2006
1	Glutamate Carboxypeptidase II (N-Acetylaspartylglutamate Peptidase)IBA 03/2006
1	EnzymesIBA 03/2006
1	Glutamic Acid (Glutamate)FDA Link 03/2006
1	poly ADP-ribose glycohydrolaseIBA 12/2005
1	Temozolomide (Temodar)FDA LinkGeneric 12/2005
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2005
1	Poly Adenosine Diphosphate RiboseIBA 07/2003
1	2-(3-mercaptopropyl)pentanedioic acidIBA 05/2003
1	Sulfhydryl Compounds (Thiols)IBA 05/2003

Therapy/Procedure

3	Therapeutics 01/2021 - 08/2013
3	Lasers (Laser) 01/2020 - 01/2013
2	Drug Therapy (Chemotherapy) 01/2021 - 12/2020
2	Diskectomy (Discectomy) 01/2020 - 10/2019
2	Surgical Instruments (Clip) 01/2020 - 10/2019
1	Perioperative Period 12/2019
1	Oral Administration 05/2003